Mustang Bio, Inc. (NASDAQ:MBIO) shares stayed put Thursday, on word that the first patient has been treated in its multicenter, open-label, non-randomized Phase 1/2 clinical trial evaluating the safety and efficacy of MB-106, Mustang’s first-in-class CD20-targeted, autologous CAR T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia.
The patient did not experience cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome.
MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center. The multicenter trial under Mustang’s Investigational New Drug Application builds upon the initial, ongoing Phase 1/2 clinical trial taking place at Fred Hutch in a single-center study under Fred Hutch’s IND.
Data shows:
An overall response rate of 96% and complete response rate of 75% in a wide range of hematologic malignancies including follicular lymphoma, CLL, diffuse large B-cell lymphoma, and Waldenstrom macroglobulinemia
Twelve patients have experienced CR for more than 12 months (10 ongoing); four patients with CR for more than two years and the longest patient with CR is at 33 months.
Six patients with partial response improved to CR and all remain in ongoing CR
All three patients previously treated with CD19 CAR T cell therapy have responded to treatment with MB-106.
MBIO shares finished Wednesday at 51 cents, and have not moved since.
